Verified peer comparison

HCA vs ABBV

HCA Healthcare, Inc. compared with AbbVie Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

HCA

HCA Healthcare, Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

ABBV

AbbVie Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

HCA: Health Care Facilities

ABBV: Biotechnology

Upside lens

HCA: Population growth and aging in HCA markets can support inpatient, outpatient and emergency demand. New beds, outpatient sites and service lines can capture demand in attractive local markets. Recruiting, retention and scheduling tools can reduce reliance on expensive contract labor.

ABBV: Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology. Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

Risk lens

HCA: Medicare, Medicaid and commercial payment changes can lag hospital cost inflation. Nurse and physician shortages can raise wages, constrain capacity and affect care quality. Billing investigations, malpractice claims and cybersecurity incidents can create material costs.

ABBV: Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition. Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand. U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.